top of page
    • Sep 23

Zurich based CDR-Life is leveraging its antibody expertise to design highly specific T-cell engagers against targets few others are able to pursue

Co-Founder & CEO Christian Leisner describes the M-gager platform and how it allows the company to have high specificity to targets, and even go after intracellular antigens displayed as small HLA peptides.



Comments

Join the BiotechTV mailing list

Thanks for subscribing!

Follow BiotechTV

  • Twitter
  • LinkedIn
  • Facebook
  • TikTok
  • Instagram

@BiotechTVHQ

BiotechTV

BiotechTVHQ

@BiotechTV

@BiotechTVHQ

Also look for unique social pages for BiotechTV U.

Sponsor Spotlight

NYSE_logo_large_no reg_378x197 (1).png

The NYSE is the world’s largest stock exchange, offering icons and entrepreneurs the opportunity to raise capital and change the world. Our listed companies form a powerful community committed to good governance and societal impact. Industry-leading trading technology, combined with the guidance of experienced traders creates higher market quality for NYSE-market participants

Visit NYSE

bottom of page